False-Negative Results in Routine Combined First-Trimester Screening for Down Syndrome in Finland

Abstract

We analyzed the frequency and possible causes of false-negative (Fn) screening results in first-trimester combined Down syndrome screening in Finland. During the study period (May 1, 2002, to December 31, 2008), 76,949 voluntary women with singleton pregnancies participated in screening. Maternal age at screening, week of gestation, levels of pregnancy-associated plasma protein-A (PAPP-A), free β-human chorionic gonadotropin (fβ-hCG), and nuchal translucency (NT) measurement were compared and statistically analyzed between true-positive (Tp) and Fn cases. There were a total of 188 Down syndrome cases (1:409) in the screened population; 154 confirmed Tp and 34 Fn cases. Most Fn cases (n = 25) occurred at 12 + 0 to 13 + 6 weeks' gestation and only nine Fn cases presented between 10 and 11 weeks' gestation. According to the logistic regression analysis, the NT measurement was the most powerful discriminating factor in Fn screening results and accounted for 37.2% of Fn results. The second most important factor was fβ-hCG, adding 14.0% to R ², followed by PAPP-A, which contributed a further 14.3%. The chosen parameters explain 83.9% of Fn results, but 16.1% remain due to unknown factor(s). All investigated parameters contributed to Fn screening results, but fetal NT was the most discriminating factor leading to an Fn screening result.

Keywords

Down syndrome - combined screening - true positive - false negative

• References

• 1 Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004; 111: 521-531
• 2 Malone FD, Canick JA, Ball RH , et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011
• 3 Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77
• 4 Hall S, Bobrow M, Marteau TM. Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study. BMJ 2000; 320: 407-412
• 5 Malin M, Gissler M. Maternal care and birth outcomes among ethnic minority women in Finland. BMC Public Health 2009; 9: 84-
• 6 Cuckle HS, van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-512
• 7 Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1990; 27 (Pt 5) 452-458
• 8 Tsukerman GL, Gusina NB, Cuckle HS. Maternal serum screening for Down syndrome in the first trimester: experience from Belarus. Prenat Diagn 1999; 19: 499-504
• 9 Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17: 821-829
• 10 Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 691-692
• 11 Terveyden ja Hyvinvoinnin Laitos. Births and newborns 2009. Available at: www.stakes.fi/tilastot/tilastotiedotteet/2010/Tr26_10pdf . Accessed November 25, 2009
• 12 Kirkegaard I, Petersen OB, Uldbjerg N, Tørring N. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat Diagn 2008; 28: 839-844
• 13 Kuc S, Koster MP, Visser GH, Schielen PC. Performance of first-trimester serum screening for trisomy 21 before and from 11 + 0 weeks of gestational age in The Netherlands. Prenat Diagn 2010; 30: 906-908
• 14 Merz E, Thode C, Alkier A , et al. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med 2008; 29: 639-645
• 15 Niemimaa M, Suonpää M, Perheentupa A , et al. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland. Eur J Hum Genet 2001; 9: 404-408
• 16 Schmidt P, Staboulidou I, Elsässer M, Vaske B, Hillemanns P, Scharf A. How imprecise may the measurement of fetal nuchal translucency be without worsening first-trimester screening?. Fetal Diagn Ther 2008; 24: 291-295